What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide derived from a partial sequence of human gastric juice protein. First isolated and characterized in the early 1990s, BPC-157 has since become one of the most-studied peptides in the regenerative-medicine literature, with research investigating its activity in tissue repair models, gastrointestinal mucosa studies, tendon and ligament repair work, and angiogenesis research.
The peptide's signature attribute in the published literature is its remarkable stability — research suggests BPC-157 retains biological activity in gastric juice for prolonged periods, which has made it a frequent subject of oral-administration study designs in animal models, in addition to the more conventional injectable subcutaneous and intramuscular routes commonly used in research protocols.
- Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids)
- Molecular Weight: ~1,419 Da
- Half-life (research): ~4 hours after subcutaneous administration in animal models
- Solubility: Bacteriostatic water for injectable research preparations
Mechanism of Action: What the Research Suggests
BPC-157's mechanism is multi-pathway and not fully resolved, but research has converged on several reproducible findings:
Angiogenesis Modulation
Multiple in vitro and animal studies have observed that BPC-157 administration is associated with upregulation of VEGF (vascular endothelial growth factor) expression and downstream pathway activation. The angiogenic effect appears to be relevant in the context of tissue-healing models, where new capillary formation is a rate-limiting step in wound resolution.
Nitric Oxide System Interaction
Research has documented BPC-157's interaction with the nitric oxide (NO) system, including modulation of eNOS and apparent counteraction of NO-system disruptions in laboratory models of vascular dysfunction. This NO-pathway activity is hypothesized to underlie some of the cardioprotective and gastroprotective findings reported in animal studies.
Growth Hormone Receptor Sensitization
A 2018 study (Chang et al.) reported that BPC-157 administration was associated with increased growth-hormone receptor expression in tendon-fibroblast culture models, providing a candidate mechanism for the tendon-repair findings observed in injury-model research.
Dopaminergic and Serotonergic System Activity
Animal-model research has noted BPC-157's apparent interaction with both dopaminergic and serotonergic signaling systems. This is mechanistically important — and is the basis for a research caution we cover below regarding co-administration with serotonin-modulating compounds.
Common Research Protocols
The published research has used a wide range of dosing in animal models, typically reported in micrograms or milligrams per kilogram of body weight. Common laboratory study designs include:
Tissue Repair Investigation Protocols
- Duration: 4–8 weeks of daily administration in published animal studies
- Route: Subcutaneous injection near the area of investigation, or oral gavage in gastric/intestinal study designs
- Endpoints: Histological tissue analysis, mechanical-property testing, biomarker quantification (collagen synthesis markers, inflammatory cytokines)
Gastrointestinal Mucosa Research
BPC-157 has been investigated in numerous gastric ulcer and inflammatory bowel disease (IBD) animal models. These protocols typically involve oral administration (leveraging BPC-157's gastric stability) over 1–4 week study durations.
Bundle Investigation Protocols
Researchers commonly pair BPC-157 with complementary peptides to investigate combined-pathway effects. The most-studied bundle pairings appear in the literature with both TB-500 (Thymosin Beta-4) and GHK-Cu (which we cover in the bundling section below).
Stacking Synergy: TB-500, GHK-Cu, IGF-1
BPC-157's mechanism is complementary to several other research peptides. The most-studied stacking pairings in the literature:
BPC-157 + TB-500 (Thymosin Beta-4)
This is the canonical research pairing. The two peptides act on parallel but distinct pathways:
- BPC-157: Acts primarily through angiogenic and NO-system pathways with relatively short half-life (~4h in animal models)
- TB-500: Modulates actin-mediated cell migration with much longer half-life
The pairing is investigated in tissue-repair research where the two peptides' temporal dynamics complement each other — BPC-157 for acute angiogenic stimulation, TB-500 for sustained cellular migration support.
BPC-157 + GHK-Cu
For research investigating extracellular matrix (ECM) remodeling, the GHK-Cu pairing adds collagen-synthesis pathway activity to BPC-157's angiogenic activity. Common in tissue-repair and dermal-research protocols. See our dermal-research stack guide for the formulated triple-blend (GHK-Cu + BPC-157 + TB-500).
BPC-157 + IGF-1 LR3
Less common but documented in regenerative-research contexts. IGF-1 LR3's anabolic-pathway activity is investigated in combination with BPC-157's repair-pathway activity for compound-effect studies. This pairing requires careful protocol design due to IGF-1's potent receptor activity.
Evaluating Research-Grade BPC-157 Supply
Not all research peptides are equal. For reproducible laboratory work, evaluating the supply chain matters as much as the compound itself. When sourcing BPC-157 for research, look for:
1. Third-Party Certificate of Analysis (COA)
A legitimate research-supply vendor will provide a COA for each batch, ideally generated by an independent lab (not an in-house test). The COA should report:
- Purity — typically reported via HPLC; research-grade BPC-157 should test ≥98%, ideally ≥99%
- Mass-spec confirmation — verifies the molecular weight matches the expected ~1,419 Da and confirms the correct compound
- Batch / lot number — links the COA to your specific vial
- Test date — recent (within ~12 months of synthesis)
Elytra Labs publishes batch-specific third-party COAs for every research peptide we ship. Browse our current COA library →
2. Storage and Stability
BPC-157 in lyophilized (freeze-dried) form is stable for 24+ months at -20°C, and several months at 2-8°C. Once reconstituted with bacteriostatic water, refrigerated stability is reported as 7-30 days depending on concentration and storage conditions. Research-grade vendors should ship lyophilized peptide with explicit storage and reconstitution guidance.
3. Reconstitution Compatibility
BPC-157 reconstitutes cleanly in bacteriostatic water (water containing 0.9% benzyl alcohol as a preservative). A clear, particulate-free solution after gentle swirling indicates a clean preparation. For long research projects, having reliable bacteriostatic water supply is non-negotiable — see our research supplies for vetted options.
Important: SSRI Considerations in Research Protocols
One topic worth flagging for research protocol design: there are reports in the peptide-research community describing apparent interactions between BPC-157 and selective serotonin reuptake inhibitors (SSRIs). The mechanistic basis is plausible — BPC-157 has documented interaction with the serotonergic system in animal models, and SSRI co-administration introduces a confounding variable in serotonin-pathway research.
For laboratory research designs investigating BPC-157, controlling for SSRI exposure (in animal models or in research-subject screening) is methodologically important to maintain reproducibility. This is not a safety claim — it's a research-design consideration.
Frequently Asked Research Questions
What's the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid synthetic peptide derived from gastric protein, primarily investigated for angiogenic and gastrointestinal-protection pathways. TB-500 is a synthetic analog of Thymosin Beta-4 (a 43-amino-acid protein) and primarily investigated for actin-mediated cell-migration pathways. They are commonly stacked in research because they act on complementary pathways with different temporal dynamics.
How is BPC-157 typically administered in research?
The two most common routes in published animal studies are subcutaneous injection (SC) and oral gavage. Research has documented activity by both routes, though pharmacokinetics differ — oral administration leverages BPC-157's unusual gastric-juice stability.
What does "research-grade" actually mean?
"Research-grade" indicates the peptide is intended for laboratory in-vitro and animal-model investigation, has been synthesized in an appropriate facility, and is accompanied by analytical documentation (purity, mass spec, batch records). It is not the same as pharmaceutical-grade or human-grade — research-grade peptides are not approved for human or veterinary therapeutic use.
How do I store BPC-157 for a long study?
For multi-month research projects: keep lyophilized peptide at -20°C in airtight conditions until reconstitution. Once reconstituted, refrigerate at 2-8°C and use within ~30 days. Avoid freeze-thaw cycles after reconstitution. For studies extending beyond 30 days, plan to reconstitute fresh aliquots periodically.
Research-Grade BPC-157 from Elytra Labs
Third-party COAs on every batch. US domestic shipping in 2-5 business days. Trusted by independent research professionals.